Theravectys
Divya BABIN
Senior VP, Business Development
Who are we?
THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market. With an extensive range of developments in infectious diseases and oncology indications,TheraVectys is positioned to profoundly and sustainably transform global health.